ArticleMcGill journal of medicine : MJM : an international forum for the advancement of medical sciences by students2008
The significance of nanoparticles in particle-induced pulmonary fibrosis.
Article in McGill journal of medicine : MJM : an international forum for the advancement of medical sciences by students, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Comprehensive Review of Nanoparticles in the Fight Against Antimicrobial Resistance.Pathogens (Basel, Switzerland) · 2025Pooled it
- Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.Critical reviews in toxicology · 2014Pooled it
- Lung cancer risk in welders and foundry workers with a history of heavy smoking in the USA: The National Lung Screening Trial.Occupational and environmental medicine · 2017Trial
- Toxicity, Cellular Uptake, and Intracellular Fate of Particulate and Dissolved Uranium in Murine Lung-Relevant Cell Models.ACS omega · 2026Article
- Regional and size-dependent effects of ambient agricultural particulate matter on Ah-receptor activity and inflammatory responses in human U937 macrophages.Inhalation toxicology · 2026Article
- Alignment of in vitro and in vivo pulmonary inflammation models using crystalline quartz silica.Particle and fibre toxicology · 2026Article
- Nanocarrier-Enabled siRNA Therapy for Pulmonary Fibrosis: Pharmacological Rationale, Delivery Barriers, and Translational Opportunities.International journal of nanomedicine · 2026Review
- Application of in vitro pulmonary models for hazard screening of silica particles.Archives of toxicology · 2025Article
- The Toxicological Profile of Active Pharmaceutical Ingredients-Containing Nanoparticles: Classification, Mechanistic Pathways, and Health Implications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Beyond cytotoxicity: pollutant mixtures elicit unconventional epithelial-fibroblast signaling in a human lung air-liquid interface co-culture model.Frontiers in toxicology · 2025Article
- Nanoparticles and Airway Epithelial Cells: Exploring the Impacts and Methodologies in Toxicity Assessment.International journal of molecular sciences · 2024Review
- Immunostimulation of Fibrous Nucleic Acid Nanoparticles Can be Modulated through Aptamer-Based Functional Moieties: Unveiling the Structure-Activity Relationship and Mechanistic Insights.ACS applied materials & interfaces · 2024Article
- Characterization of dental dust particles and their pathogenicity to respiratory system: a narrative review.Clinical oral investigations · 2023Review
- The dependence of particle size on cell toxicity for modern mining dust.Scientific reports · 2023Article
- Establishing relationships between particle-induced in vitro and in vivo inflammation endpoints to better extrapolate between in vitro markers and in vivo fibrosis.Particle and fibre toxicology · 2023Article
- Airborne LTA Nanozeolites Characterization during the Manufacturing Process and External Sources Interaction with the Workplace Background.Nanomaterials (Basel, Switzerland) · 2022Article
- LongitudinalFrontiers in bioengineering and biotechnology · 2022Article
- Nanotechnology and its use in imaging and drug delivery (Review).Biomedical reports · 2021Review
- Biocompatibility of nanomaterials and their immunological properties.Biomedical materials (Bristol, England) · 2021Review
- Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exposure to airborne nanoparticles contributes to many chronic pulmonary diseases. Nanoparticles, classified as anthropogenic and natural particles, and fibers of diameters less than 100 nm, have unrestricted access to most areas of the lung due to their size. Size relates to the deposition efficiency of the particle, with particles in the nano-range having the highest efficiencies. The deposition of nanoparticles in the lung can lead to chronic inflammation, epithelial injury, and further to pulmonary fibrosis. Cases of particle-induced pulmonary fibrosis, namely pneumoconiosis, are mostly occupationally influenced, and continue to be documented around the world. The tremendous growth of nanotechnology, however, has spurred fears of increased rates of pulmonary diseases, especially fibrosis. The severity of toxicological consequences warrants further examination of the effects of nanoparticles in humans, possible treatments and increased regulatory measures.
Indexed as
Identifiers
18523535PMC2322933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.